Search
Myriad Genetics Inc
MYGNAdd to Watchlist
4.170USD
+0.030+0.72%
Close 09-25 16:00（ET）
393.86MMarket Cap
LossP/E TTM
After-hours 18:53 (ET)4.100USD-0.070-1.68%
After-hours 18:53 (ET)Myriad Genetics Inc (MYGN) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Myriad Genetics Inc in the past month.
Hold
0 Strong Buy
1 Buy
6 Hold
2 Sell
1 Strong Sell
Target Price
3.367USD-16.04%
MYGN Analyst Recommendation Trends
In the current month, MYGN has received 1 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. MYGN average Analyst price target in the last month is 3.367.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
1
2
2
2
2
3
3
3
6
6
6
7
7
7
7
7
1
1
1
1
1
1
1
1
2
1
1
1
2
2
2
2
10
10
10
11
12
13
13
13
MYGN Analyst Rating for Peer Comparison
Updated: Sep 26, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Dexcom Inc
DXCM
13
13
4
0
0
30
Stryker Corp
SYK
11
13
6
0
0
30
Medtronic PLC
MDT
9
10
11
0
0
30
Zimmer Biomet Holdings Inc
ZBH
2
6
21
0
0
29
Medline Ord Shs Class A
MDLN
10
12
6
0
0
28
Abbott Laboratories
ABT
11
12
5
0
0
28
Insulet Corp
PODD
7
8
12
0
0
27
Guardant Health Inc
GH
12
13
2
0
0
27
Tandem Diabetes Care Inc
TNDM
5
8
10
0
0
23
Repligen Corp
RGEN
5
14
3
0
0
22
Financial Forecasting
Based on analysts' estimates, MYGN EPS is projected to reach -0.208 in FY2026Q3, following reported EPS of -0.456 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.01
-0.07
-0.06
-0.21
-0.19
Actual
-0.08
-0.36
-0.46
--
--
Surprise
-477.91%
-431.91%
-687.18%
--
--
FAQs
What is Myriad Genetics Inc's expected revenue for the next quarter?
Myriad Genetics Inc's expected revenue is 191.43M.
What is Myriad Genetics Inc's price target?
Analysts forecast that Myriad Genetics Inc's price target is USD 3.37, with the highest forecast at USD 5.00 and the lowest forecast at USD 2.00.
How have Myriad Genetics IncMYGN's recent earnings per share performed?
The market expectation was USD -0.46, while Myriad Genetics IncMYGN's earnings per share (EPS) for the previous quarter was USD -0.36. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for Myriad Genetics Inc?
Based on the ratings of Myriad Genetics Inc's stock from 10 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.